Minimizing Toxicities & Improving Tolerability to Bring More ADCs With a Wider Therapeutic Index to Market

Welcome to the Inaugural ADC Toxicity Summit

Delivering More Tolerable ADCs to Patients

Toxicity remains the single biggest hurdle in getting ADCs to market, and drug developers are striving to develop safer antibody drug conjugates while keeping efficacy high. Although ADCs have come far, there are still more advancements to be made, highlighted by the blockbuster Enhertu and the recently approved Elahere, both containing Black Box Warnings.

Created for all key stakeholders in this conversation, from pathology and toxicology to translation, nonclinical and clinical development, the ADC Toxicity Summit is the first and only event dedicated to providing case-study-led presentations and interactive discussions, enabling you to arm you with all the information you could need to maximize your therapeutic windows, from discovery to early clinical.

From finding optimal in vivo and in vitro models, managing and mitigating toxicities in the clinic, to finding ideal ADC design and dosage regimes, the ADC Toxicity Summit will arm you with all you need to widen your therapeutic windows and get therapies to market faster.

Expert Speaking Faculty Includes:

Companies Attending This Meeting:

ALX Oncology
Mersana Therapeutics
Mablink Bioscience Logo
Merck & Co
Loxo Oncology
MBrace Therapeutics
Eli Lilly & Co.
Exelixis No B
Araris Logo (002)
Tacalyx GmbH
OBI Pharma
Zentalis Pharmaceuticals

Part of the World ADC Series:

As part of the World ADC series - a platform that plows its collective energy into sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distill this into accessible formats of information exchange – for you. From globally leading conferences to webinars and industry reports, whatever the information you need,  ADC Toxicity Summit can offer you the insights you need to accelerate your ADC drug development into the clinic through to market.

world adc 2
Screenshot 2023-03-09 181258
world adc

2023 Event Partner:

What Your Peers Have to Say:

“An outstanding must-attend ADC Toxicity conference, with excellent networking, incredible science, and great speakers from both academic and biopharmaceutical sectors, offering exciting research and case studies on understanding the critical toxicity issues and mitigation strategies”

Rakesh Dixit, Bionavigen

Other Events In The Series